Glenmark Pharmaceuticals Ltd. share price target

US Business: Improvement in US business (up 25% yoy & 10% qoq) is driven by multiple factors such as: strong gain in market share in gCrestor, ramp-up in recently launched products, gMupirocin sales improvement, strong traction in derma (new launches: T-Cream, gDiclofenac, gLidocaine) and other products. Management believes that the price erosion in base business stood at 10% on account of increased approvals by the US FDA. It further expects most future launches (till FY19E) would be from derma segment, as it believes that post FY19E, the Company will see more launches in complex generic space (injectables)....

Total revenues for Q2FY17 were up 16.48%/14.4% YoY/QoQ at Rs22.2 bn in-line with our estimates triggered by growth across key geographies, however, entire EM ex-India continued to get impacted on account of currency devaluation . EBITDA margin declined 97bps YoY and up 67bps QoQ from 21.1% in Q2FY16 to 20.2% in current quarter mainly due to the continuing pricing pressure in the base business. It was down 120bps against our guidance was due mainly to higher than expected Staff Costs (payment of variable pays, annual increments and addition in employees). But we believe an improvement in the margins attributable also to the better product mix....

Glenmarks strong top line performance (16% YoY) and sequential improvement in profitability led to 24% YoY earnings growth in 1QFY17. Revenues increased to Rs 18.8bn with US business growing at 24% YoY.

Key highlights: Revenues were 3% below our estimates to Rs 19.43bn (+18% yoy). While US sales of US$ 104mn (+24% yoy) was in line of our estimates and Domestic formulations outpaced industry growth, the weak show by Latin America markets led to miss in sales estimates. Visible pricing pressure in US & higher employee cost caused 270bps negative surprise in operating margin at 19.5% (estimated 22.2%) that resulted in 15% below expected EBITDA at Rs 3.79bn. Thanks to forex gain of Rs700mn that supported PAT at Rs 2.18bn (10% below estimated). However, the tax rate was higher at 35% (vs 25% normal). The core earnings (adjusted forex gain and abnormal taxes) were 18% below expectation.Phillip Capital now value GNP at Rs 1000 i.e.19x FY18 EPS, implying 18% potential upside. Re?iterate BUY with a lowered TP of Rs 1000.

ICICI Securities Ltd | Retail Equity Research Revenues grew 17.9% YoY to | 1943.1 crore (I-direct estimate: | 2021.9 crore) mainly due to 24.4% YoY growth in the US to | 698.2 crore (I-direct estimate: | 698.8 crore). India business grew 10.4% YoY to | 513.8 crore (I-direct estimate: | 520.2 crore) EBITDA margins declined 230 bps YoY to 19.5% (I-direct estimate: 21.1%) due to lower gross margins, higher employee cost. EBITDA rose mere 5.5% YoY to | 379.1 crore (I-direct estimate: | 427.0 crore)...

Glenmark Pharmaceuticals' (GNP) Sales, EBITDA & PAT stood at Rs19.4bn, Rs3.8bn & Rs2.2bn, respectively in 1QFY17. Revenue from US business (~37% of sales) rose 18% yoy to US$104mn in 1QFY17 (vs. US$97mn in Q4FY16 & US$89mn in Q1FY16) due to new product approvals. Revenue from India business (~27% of sales) grew by just 10% yoy to Rs5.1bn due to adverse impact of New Pricing Policy and ban on several fixed dose combinations. Revenue from semi-regulated markets (10% of sales) grew 23% yoy due to strong growth in Russia (50% yoy in CC terms). LatAm (~8% of sales) degrew 29% yoy due to negligible contribution from Venezuela and weak performance in Brazil...

off the EBITDA was ~Rs. 460 crore i.e. 20% of revenues. Adjusted for these, margins improved 310bps. Adjusted net profit grew Avg. daily volume (1yr. on NSE)...

Revenues grew 28.5% YoY to | 2281.3 crore (I-direct estimate: | 1849.6 crore) mainly on account of robust growth across geographies. The company witnessed 21.6% YoY growth in the US to...

ROW (+36%) and LatAm (+34%) sales. US sales of US$ 97mn were inline with our estimates.CoreoperatingmarginadjustingforforexlossofRs840mnandonetime SitagliptinrelatedlitigationcostofRs650mn)compressedby~260bpsyoyto19.8%...

However, margin performance was just about in line as improving revenue mix towards bettermargindomestic/USbusinessraisedEBITDAmarginsby80bpsto22.6%.Ledbylower salesandhighertaxincidenceof33%,PAT(adjustedforforexlossofRs270mn)was19%...